The ASX 200 (INDEXASX: XJO)(^AXJO) is expected to open higher today, the USA’s S&P 500 Index (.INX) fell by 0.16% on Friday.
Australian Dollar ($A) (AUDUSD): 68.74US cents
Dow Jones (DJI): down 0.07%
Oil (WTI): $US52.65 per barrel
Gold: $US1,342 per ounce
ASX Sharemarket News
In ASX sharemarket news, fintech business Hub24 Ltd (ASX: HUB) has said that it has seen an increase in fund flows since the election result according to the Australian Financial Review.
Hub24 is benefiting from the change since the Royal Commission with advisers trying to shift away from the big financial advice businesses like AMP Limited (ASX: AMP).
HUB24 Managing Director Andrew Alcock said: “We have seen greater activity, yes. Things were slower and patchier before the election than they were after the election; it appears the stability in government might be driving some confidence. Advisers can’t continue to service the same amount of clients without becoming more efficient.”
[ls_content_block id=”15758″ para=”paragraphs”]
Australia and New Zealand Banking Group (ASX: ANZ) New Zealand CEO David Hisco has been fired for issues relating to personal expenses.
ANZ said that whilst Mr Hisco does not accept all of the concerns raised by the Board, he has accepted accountability given his leadership position and agrees the “characterisation” of the expenses falls short of the standards required.
ANZ New Zealand Chair Rt Hon Sir John Key said: “We are disappointed David is leaving ANZ under such circumstances after such a long career, however his departure is the right one in these circumstances given the expectations we have of all our people, no matter how senior or junior.”
Antonia Watson has been appointed the acting CEO of ANZ New Zealand.
Popular Stories:
- How Much Will Afterpay (APT) Shares Be Worth In 2022?
- The Australian Investors Podcast – Scott Williams
- Which Magellan Fund Should I Buy — (ASX:MFF) vs (ASX:MGG)?
- Is It Time To Get A Fixed Mortgage Interest Rate?
Cochlear Limited (ASX: COH) has announced today that it has received FDA approval for the Nucleus Profile Plus Series cochlear implact.
The hearing device business said it will commence an immediate US launch.
[ls_content_block id=”14945″ para=”paragraphs”]
[ls_content_block id=”18380″ para=”paragraphs”]
